drugset
drugset / Trial / NCT06084884

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06084884 ↗

Phase 1/2 Active not recruiting 94 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.

Timeline

Start
2023-12-14
Primary completion
2027-12-13
Completion
2027-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5851 Cell therapy — Intravenous

Indications

hepatocellular carcinoma